Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP51A1 | Q16850 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | SMO | Q99835 | 2/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.34 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26048600 | 0.88 | PTGS2 (0.41) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL23157402 | 0.83 | IDO1 (0.48) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL22683759 | 0.83 | CYP51A1 (0.42) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL30874461 | 0.79 | CYP51A1 (0.49) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL15590856 | 0.79 | CYP51A1 (0.49) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL16288084 | 0.79 | CA1 (0.41) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL16288086 | 0.79 | CA1 (0.41) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL16748959 | 0.78 | CA1 (0.58) | CYP51A1CA1CA2CA5ACA9 | |
| SCHEMBL23150490 | 0.76 | TSHR (0.40) | TSHRNOX1 | |
| SCHEMBL23157115 | 0.76 | TP53 (0.42) | CYP51A1CA1CA2CA5ACA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021216722-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2021-10-28 | — | — | WO | claimed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRONINSTITUT DE RECERCA (ES) | 2024-06-11 | — | — | US | disclosed |
| WO-2024083861-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | SELABTEC SCIENCES, SLU (ES) | 2024-04-25 | — | — | WO | disclosed |
| EP-4356909-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | Selabtec Sciences, SLU (ES) | 2024-04-24 | — | — | EP | disclosed |
| EP-3271468-B1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION SL (ES) | 2022-12-14 | — | — | EP | disclosed |
| EP-3813832-B1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | FUNDACIO HOSPITAL UNIV VALL DHEBRON INSTITUT DE RECERCA (ES) | 2022-11-09 | — | — | EP | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
| CN-107849594-B | Deamination of organophosphorus nucleosides | 科技学专业学院有限公司 | 2022-01-18 | — | — | CN | disclosed |
| US-20210230150-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | AMIRA THERAPEUTICS, S.L. (ES) | 2021-07-29 | — | — | US | disclosed |
| EP-3813832-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (ES) | 2021-05-05 | — | — | EP | disclosed |
| US-20180066295-A1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | LABORATORIO TECNICO DE SEGURIDAD Y ESTANDARIZACION, S.L.U. (ES) | 2018-03-08 | — | — | US | disclosed |
| EP-3271468-A1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | Institut Univ. de Ciència i Tecnologia, S.A. (ES) | 2018-01-24 | — | — | EP | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| WO-2016146808-A1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | INSTITUT UNIV. DE CIÈNCIA I TECNOLOGIA, S. A. (ES) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230150-A1 | COMPOUNDS FOR USE IN PREVENTING OR TREATING CANCER | UGT1A3, UGT1A1, UGT1A6 | CYP51A1 152/4885CA1 1027/4885CA2 1624/4885 |
| US-12006311-B2 | Compounds for use in preventing or treating cancer | UGT1A3, UGT1A1, UGT1A6 | CYP51A1 152/4885CA1 1027/4885CA2 1624/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | CYP51A1 591/4885CA1 3481/4885CA2 4828/4885 |
| US-20180066295-A1 | DEAMINATION OF ORGANOPHOSPHORUS-NUCLEOSIDES | ADA, CDA, DCTD | CYP51A1 626/4885CA1 1878/4885CA2 1256/4885 |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | HDGF, F11, F12 | CYP51A1 591/4885CA1 3481/4885CA2 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.